Literature DB >> 19339245

Identification of a novel Zn2+-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin.

Ventzislava A Hristova1, Steven A Beasley, R Jane Rylett, Gary S Shaw.   

Abstract

Missense mutations in park2, encoding the parkin protein, account for approximately 50% of autosomal recessive juvenile Parkinson disease (ARJP) cases. Parkin belongs to the family of RBR (RING-between-RING) E3 ligases involved in the ubiquitin-mediated degradation and trafficking of proteins such as Pael-R and synphillin-1. The proposed architecture of parkin, based largely on sequence similarity studies, consists of N-terminal ubiquitin-like and C-terminal RBR domains. These domains are separated by a approximately 160-residue unique parkin sequence having no recognizable domain structure. We used limited proteolysis experiments on bacterially expressed and purified parkin to identify a new domain (RING0) within the unique parkin domain sequence. RING0 comprises two distinct, conserved cysteine-rich clusters between Cys(150)-Cys(169) and Cys(196)-His(215) consisting of CX(2)-(3)CX(11)CX(2)C and CX(4-6)CX(10-16)-CX(2)(H/C) motifs. The positions of the cysteine/histidine residues in this region bear similarity to parkin RING1 and RING2 domains, as well as other E3 ligase RING domains. However, in parkin a 26-residue linker region separates the motifs, which is not typical of other RING domain structures. Further, the RING0 domain includes all but one of the known ARJP mutation sites between the ubiquitin-like and RBR regions of parkin. Using electrospray ionization mass spectrometry and inductively coupled plasma-atomic emission spectrometry analysis, we determined that the RING0, RING1, IBR, and RING2 domains each bind two Zn(2+) ions, the first observation of an E3 ligase with the ability to bind eight metal ions. Removal of the zinc from parkin causes near complete unfolding of the protein, an observation that rationalizes cysteine-based ARJP mutations found throughout parkin, including RING0 (C212Y) that form cellular inclusions and/or are defective for ubiquitination likely because of poor zinc binding and misfolding. The identification of the RING0 domain in parkin provides a new overall domain structure for the protein that will be important in assessing the roles of ARJP mutations and designing experiments aimed at understanding the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339245      PMCID: PMC2685680          DOI: 10.1074/jbc.M808700200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

Review 1.  Zinc fingers--folds for many occasions.

Authors:  Jacqueline M Matthews; Margaret Sunde
Journal:  IUBMB Life       Date:  2002-12       Impact factor: 3.885

2.  NMR structure of ubiquitin-like domain in PARKIN: gene product of familial Parkinson's disease.

Authors:  Mitsuru Tashiro; Seiji Okubo; Sakurako Shimotakahara; Hideki Hatanaka; Hideyo Yasuda; Masatsune Kainosho; Shigeyuki Yokoyama; Heisaburo Shindo
Journal:  J Biomol NMR       Date:  2003-02       Impact factor: 2.835

3.  The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates.

Authors:  Wen-Jie Gu; Olga Corti; Francisco Araujo; Cornelia Hampe; Sandrine Jacquier; Christoph B Lücking; Nacer Abbas; Charles Duyckaerts; Thomas Rooney; Laurent Pradier; Merle Ruberg; Alexis Brice
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

Review 4.  A potential proteasome-interacting motif within the ubiquitin-like domain of parkin and other proteins.

Authors:  Sudarshan C Upadhya; Ashok N Hegde
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

Review 5.  Parkin and relatives: the RBR family of ubiquitin ligases.

Authors:  Ignacio Marín; J Ignasi Lucas; Ana-Citlali Gradilla; Alberto Ferrús
Journal:  Physiol Genomics       Date:  2004-05-19       Impact factor: 3.107

6.  Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.

Authors:  Yien Che Tsai; Paul S Fishman; Nitish V Thakor; George A Oyler
Journal:  J Biol Chem       Date:  2003-04-03       Impact factor: 5.157

7.  Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.

Authors:  Yong Ren; Jinghui Zhao; Jian Feng
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

8.  SEPT5_v2 is a parkin-binding protein.

Authors:  P Choi; H Snyder; L Petrucelli; C Theisler; M Chong; Y Zhang; K Lim; K K K Chung; K Kehoe; L D'Adamio; J M Lee; E Cochran; R Bowser; T M Dawson; B Wolozin
Journal:  Brain Res Mol Brain Res       Date:  2003-10-07

9.  How much phenotypic variation can be attributed to parkin genotype?

Authors:  Ebba Lohmann; Magali Periquet; Vincenzo Bonifati; Nick W Wood; Giuseppe De Michele; Anne-Marie Bonnet; Valérie Fraix; Emmanuel Broussolle; Martin W I M Horstink; Marie Vidailhet; Patrice Verpillat; Thomas Gasser; David Nicholl; Hélio Teive; Salmo Raskin; Olivier Rascol; Alain Destée; Merle Ruberg; Francesca Gasparini; Giuseppe Meco; Yves Agid; Alexandra Durr; Alexis Brice
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

10.  The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI.

Authors:  Duong P Huynh; Daniel R Scoles; Dung Nguyen; Stefan M Pulst
Journal:  Hum Mol Genet       Date:  2003-08-12       Impact factor: 6.150

View more
  61 in total

Review 1.  Regulation of Parkin E3 ubiquitin ligase activity.

Authors:  Helen Walden; R Julio Martinez-Torres
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

Review 2.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

3.  Differential interaction of the E3 ligase parkin with the proteasomal subunit S5a and the endocytic protein Eps15.

Authors:  Susan S Safadi; Gary S Shaw
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

4.  Selective escape of proteins from the mitochondria during mitophagy.

Authors:  Shotaro Saita; Michiko Shirane; Keiichi I Nakayama
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Parkin mitochondrial translocation is achieved through a novel catalytic activity coupled mechanism.

Authors:  Xinde Zheng; Tony Hunter
Journal:  Cell Res       Date:  2013-05-14       Impact factor: 25.617

Review 6.  Twenty years since the discovery of the parkin gene.

Authors:  Nobutaka Hattori; Yoshikuni Mizuno
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

Review 7.  Targeting Pink1-Parkin-mediated mitophagy for treating liver injury.

Authors:  Jessica A Williams; Wen-Xing Ding
Journal:  Pharmacol Res       Date:  2015-10-24       Impact factor: 7.658

8.  PINK1 is selectively stabilized on impaired mitochondria to activate Parkin.

Authors:  Derek P Narendra; Seok Min Jin; Atsushi Tanaka; Der-Fen Suen; Clement A Gautier; Jie Shen; Mark R Cookson; Richard J Youle
Journal:  PLoS Biol       Date:  2010-01-26       Impact factor: 8.029

9.  PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy.

Authors:  Noriyuki Matsuda; Shigeto Sato; Kahori Shiba; Kei Okatsu; Keiko Saisho; Clement A Gautier; Yu-Shin Sou; Shinji Saiki; Sumihiro Kawajiri; Fumiaki Sato; Mayumi Kimura; Masaaki Komatsu; Nobutaka Hattori; Keiji Tanaka
Journal:  J Cell Biol       Date:  2010-04-19       Impact factor: 10.539

Review 10.  Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.

Authors:  Britney N Lizama; Amy M Palubinsky; BethAnn McLaughlin
Journal:  Neurochem Int       Date:  2017-08-26       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.